Clinical Landscape of T Cell Bispecifics in Solid Tumors

T cell bispecifics are a promising class of immunotherapies that have demonstrated survival benefit across multiple hematologic malignancies and are now emerging in solid tumors. The learning objectives of this session will be to review the mechanism of action, describe toxicities, and evaluate mechanisms of resistance of T cell bispecifics. The presentation will seek to apply lessons learned from hematologic malignancies as well as from past and ongoing trials in solid tumors to the development of these agents in solid tumor oncology.

Learning Objectives:

1. Summarize the mechanisms of action of T cell bispecifics. 

2. Describe toxicities of T cell bispecifics. 

3. Evaluate mechanisms of resistance of T cell bispecifics.